Luye Pharma grants commercialization rights for antipsychotics in China

Luye Pharma Group Ltd. has announced a ten-year agreement granting its subsidiary, Jiangsu Nhwa Hexin Pharmaceutical Marketing Co., Ltd., exclusive rights to commercialize three long-acting injectable (LAI) antipsychotics in the Chinese mainland. The products, Rykindo, Ruibailai, and Meibirui, are all indicated for schizophrenia.

Under the terms of the agreement, Nhwa will manage the distribution and commercialization, while Luye Pharma retains ownership of the product assets, marketing authorizations, and intellectual property rights, remaining responsible for manufacturing and supply. Luye Pharma Group will receive a one-time, non-refundable licensing fee of $20m from Nhwa upon the agreement’s signing.

This partnership combines two prominent players in China's central nervous system (CNS) therapeutic field, aiming to expand market access for these treatments and enhance patient care for schizophrenia.